569 results about "Genetically modify" patented technology

The disclosure encompasses genetically modified plants and methods for improving phosphorus redistribution and use efficiency. The genetically modified plants increase the expression of a nonspecific phospholipase C4 (NPC4) protein, enhancing phosphorus remobilization from old, senescing tissues to young, growing tissues and seeds. The genetic modification improves plant growth, increases seed and oil yield, and alters fatty acid composition. The genetically modified plants demonstrate enhanced phosphorus use efficiency under phosphorus-limited conditions, showing greater growth and yield improvements compared to wild-type plants. Specifically in camelina plants, the genetic modification increases seed yield, elevates oil content, and alters fatty acid composition of the oil under P-limited conditions.

The present disclosure provides a population of CD4IL-10 / CAR cells (autologous or allogeneic single-donor and allogeneic polydonor) generated by genetically modifying CD4+ Tcells to express IL-10 and a chimeric antigen receptor. Further provided are methods of generating the CD4IL-10 / CAR cells and methods of using the CD4IL-10 / CAR cells for immune tolerization, treating GvHD, cell and organ transplantation, cancer, and autoimmune and inflammatory disorders.

A chimeric autoantibody receptor (CAAR) that enables targeting of an immune cell to autoantibody producing B cells. The CAAR includes an autoantigen or fragment thereof that is bound by autoantibodies associated with neurological autoimmune disease primarily targeting the central nervous system. Also disclosed is a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), the nucleic acid sequence encoding an autoantigen or fragment thereof that is bound by autoantibodies associated with a neurological autoimmune disease primarily targeting the central nervous system, a transmembrane domain, and an intracellular signaling domain, a vector comprising a nucleic acid molecule encoding a chimeric autoantibody receptor (CAAR), a genetically modified immune cell comprising the nucleic acid molecule encoding the CAAR and use of the immune cell in the treatment or prevention of a neurological autoimmune disease primarily targeting the central nervous system, such as an autoimmune encephalopathy or encephalomyelopathy, preferably anti-NMDAR encephalitis.

Disclosed herein is a method for producing a lipid or oil in a plant, the method comprising genetically modifying the plant to express a plurality of heterologous proteins selected from PaWRI1, PaWRI2, PaDGAT1, or PaPDAT1, or variants thereof. The expression of the plurality of heterologous proteins in the genetically modified plant may result in a change in the nutrient profile of the plant relative to non-genetically modified plants of the same species. Also disclosed herein is a method for producing fatty acid and triacylglycerol content in plant non-seed tissue. Further disclosed herein is a method for producing a genetically modified plant.

Compositions and methods for treating diseases associated with expression of a cancer associated antigen are disclosed. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, SHP inhibitory molecules, vectors encoding the same, and recombinant immune effector cells comprising the CARs and SHP inhibitory molecules. Methods of administering a genetically modified immune effector cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen and a SHP inhibitory polypeptide are also disclosed.

The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.

An isolated cell having a central memory T-lymphocyte (Tcm) phenotype, the cell being tolerance-inducing cell and capable of homing to the lymph nodes following transplantation, the cell being transduced to express a cell surface receptor comprising a T cell receptor signaling module is described. Methods of generating same and using same are also described.

The invention discloses a medicine composition for inducing fibroblasts to be reprogrammed into pericyte-like cells (PCLCs) through a chemical small molecule combination, and the medicine composition is used for treating sepsis. According to the invention, a chemical reprogramming strategy without genetic modification is adopted, an endogenous signal channel is activated through a time sequence, and fibroblasts from somatic cells are efficiently converted into PCLCs with high expression of genes such as EMILIN3, LAMC3, GDF10, AHR, CD109, AHR, NQO1, QPRT and the like. When applied to treatment of sepsis, the medicine composition can improve pathological symptoms and reduce death rate by synergistically exerting anti-inflammatory, anti-oxidation, immune regulation and tissue barrier protection effects. The invention provides a novel safe treatment strategy based on non-genetically modified cells for sepsis.

The present invention relates to methods for making compounds of formula (I) including violacein, violacein analogues and derivatives thereof, and to compositions, cells, and fermentation liquids comprising the compounds resulting from these methods.

The invention relates to a method for inhibiting rumen gas production by using a genetically modified laver filament as a ruminant feed additive and a method for inhibiting methane production by using the genetically modified laver filament as the ruminant feed additive. A porphyra yezoensis bromine peroxidase gene is cloned, an overexpression vector of the gene is constructed, porphyra yezoensis thallus is used as a receptor for genetic transformation, and a porphyra algal strain of which the key enzyme expression quantity is remarkably improved is obtained through screening. The method comprises the following steps: inducing thalli to generate protonema, crushing the protonema by using a crusher, carrying out ventilated large-scale culture in a seawater culture medium added with PES by using a column bioreactor to obtain a large number of protonema materials, collecting the protonema materials, crushing the protonema materials by using the crusher, and drying at low temperature. The obtained laver protonema powder is put into a vacuum bag for low-temperature preservation in dark light, and can be applied to preparation of ruminant feed as a dairy cow feed additive. The filamentous can accumulate halogenated compounds such as bromidogen and the like, can inhibit the activity of a key enzyme generated by methane in rumen, and further inhibits the generation of methane.

The invention relates to a gene modified cell for producing HMOs, which can be applied to synthesis of difucosyllactose, and belongs to the technical field of gene engineering. The invention provides a genetically modified cell, which contains an alpha-1, 2-fucosyltransferase polypeptide and a heterologous nucleic acid sequence of the alpha-1, 3-fucosyltransferase polypeptide. The genetically modified cell has higher activity of synthesizing difucosyllactose, and does not contain synthetic 3-fucosyllactose or lower side activity of synthetic 2 '-fucosyllactose. The technical scheme of the invention has positive significance for industrial production of human milk oligosaccharide, and the method is green, efficient and sustainable, is beneficial to industrial large-scale production, and has important practical value.

The present disclosure provides stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., T cells, B cells, natural killer cells, to genetically modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

A genetically modified yeast cell, wherein the yeast cell comprises a genetic modification comprising overexpression of yeast gene encoding porphobilinogen deaminase (HEM3), the HEM3 gene having at least 80% identity with SEQ ID No. 7. The genome of the modified yeast cell further comprises one or more genetic modifications in one or more genes selected from: genes coding for heme-dependent repressor of hypoxic genes (ROX1), genes coding for heme oxygenase (HMX1), genes coding for a receptor for vacuolar proteases (VPS10), and genes coding for vacuolar proteinase (PEP4), the one or more genetic modifications being such that expression of a polypeptide from such a gene is reduced or disrupted or the polypeptide expressed is non-functional.

The present invention relates to an artificially manipulated unsaturated fatty acid biosynthesis-associated factor and use thereof to increase the content of a specific unsaturated fatty acid of a plant body. More particularly, the present invention relates to a system capable of artificially controlling unsaturated fatty acid biosynthesis and a plant body produced thereby, which include an artificially manipulated unsaturated fatty acid biosynthesis-associated factor to control unsaturated fatty acid biosynthesis and a composition capable of artificially manipulating the factor. In a specific aspect, the present invention relates to artificially manipulated unsaturated fatty acid biosynthesis-associated factors such as FAD2, FAD3, FAD6, FAD7 and FAD8 and / or an unsaturated fatty acid biosynthesis controlling system by an expression product thereof.

In various embodiments, provided herein are host cells, methods, and pharmaceutical compositions comprising gastrodin, wherein the gastrodin is produced by a genetically modified plant or plant cell, fungal cell, yeast cell, insect cell, or bacterial cell. In certain embodiments, the present disclosure provides methods and compositions for the production of gastrodin. In yet other embodiments, the present disclosure provides enhanced cells and methods for producing gastrodin.

This invention provides engineered natural killer (NK) cells and methods for producing engineered NK cells. [Solution] The present invention provides engineered natural killer (NK) cells, which are genetically modified to reduce the expression, activity, and / or signaling of the FcRγ chain in the cells. The engineered NK cells and compositions comprising the engineered NK cells are useful for treating diseases such as cancer.

The disclosure provides methods of treating a malignancy comprising administering an effective dose of a chimeric antigen receptor genetically modified T cell immunotherapy and methods for manufacturing such immunotherapy. Some aspects of the disclosure relate to methods of determining objective response of a patient to a T cell immunotherapy based on the levels of attributes prior to and after administration of the immunotherapy to the patient.

This invention discloses a cultivation and monitoring device for low-temperature cold-resistant growth of rice, relating to the field of rice cultivation technology. The invention includes a three-layer frame for mounting the equipment; a supplementary lighting system is installed on the upper layer of the frame; a rice cultivation trough is installed on the middle layer; and a water tank and a chiller are installed on the lower layer. The water tank and the chiller's inlet are connected via a first pipe. The rice cultivation trough is internally divided into a cold water inlet chamber, a cold water cultivation chamber, and a cold water return chamber. Water level and flow are controlled by inlet and outlet weirs. The device is also equipped with adjustable weirs to flexibly adjust the water level to meet the needs of different rice growth stages. Simultaneously, a video recording device and a temperature recording device are installed to record the entire rice growth process and monitor water temperature in real time, providing researchers with accurate experimental data. Furthermore, the device includes a room-temperature cultivation chamber as a control, which helps evaluate the low-temperature growth ability of genetically modified or hybridized rice seeds.

Genetically modified cells that are compatible with multiple subjects, e.g., universal donor cells, and methods of generating said genetic modified cells are provided herein. The universal donor cells comprise at least one genetic modification within or near at least one gene that encodes a survival factor, wherein the genetic modification comprises an insertion of a polynucleotide encoding a tolerogenic factor. The universal donor cells may further comprise at least one genetic modification within or near a gene that encodes one or more MHC-I or MHC-II human leukocyte antigens or a component or a transcriptional regulator of a MHC-I or MHC-II complex, wherein said genetic modification comprises an insertion of a polynucleotide encoding a second tolerogenic factor.

This invention discloses a rapeseed BnaALaAT1 The application of genes in breeding stress-resistant, high-yielding plant varieties, the aforementioned BnaALaAT1 The nucleotide sequence of the gene is shown in SEQ ID NO.1. This invention clones the versatile gene from rapeseed. BnaALaAT1 We constructed pure-line plants by introducing rapeseed and conducted phenotypic investigations under various conditions. The experimental results showed that... BnaALaAT1 Genetically modified rapeseed exhibits significantly superior growth compared to the wild type under both normal and various adverse conditions, fully demonstrating that this gene can enhance the plant's survival ability under various adverse conditions by regulating the plant's response mechanism to multiple stresses, providing a crucial guarantee for the stable growth of plants under diverse adverse conditions. Compared to the wild type, transgenic plants not only show a significant increase in yield, with a maximum increase of 53.7%, but also a significant increase in oil content.

The present application relates to the technical field of intelligent identification system of crop pests, in particular to a plant field pest fine-grained identification method, system, device and storage medium based on deep learning. The identification method provided by the present application is specialized in high-precision identification of real field scenes, and can provide technical support for important work such as future development of field inspection robot, automatic identification and monitoring system of field pests and the like. In addition to pest monitoring, the field biological safety test of genetically modified plants is gradually carried out at present, and by using the identification method provided by the present application, the dynamic change of farmland insect community can be quickly and accurately identified and predicted, so that the efficiency and accuracy of ecological investigation are greatly improved.

Provided herein are compositions and methods for real-time identification and isolation of base-edited cell populations. Also provided herein are methods for producing enriched isogenic lines of genetically modified cells, including base-edited human pluripotent stem cells. In particular, provided herein are methods utilizing transient expression of reporter proteins, the detectable signal of which is altered following base editing. Using the transient reporter with a base editor permits enrichment of isogenic populations of base-edited cells.

The present disclosure relates to deoxyribonucleic acid (DNA) editing agents, and their use in preparing genetically modified cells and birds. The present disclosure further relates to fertile genetically modified avians and genetically modified avian primordial germ cells (PGCs) for producing sterile genetically modified avians (birds) that can serve as surrogate hosts for donor PGCs. The present disclosure further relates to methods for producing fertile avian strains that can produce a population of embryos and offspring, in both sexes, all of which are sterile and viable, and further relates to their subsequent use as sterile surrogate hosts for donor PGCs.

The present invention relates to a recombinant antisense oligonucleotide that targets CD33 mRNA and to a method of preparing a substantially pure population of edited eukaryotic cells comprising the steps of i) editing a population of eukaryotic cells by the use of base editors, (ii) treating the same population with antisense oligonucleotides according to the invention to transiently downregulate CD33 and iii) enriching the population of edited eukaryotic cells that is negative for CD33.

Disclosed is a genetically modified rodent, in which an immunoglobulin light chain locus is modified to insert a human immunoglobulin light chain gene segment. The rodent is capable of normal reproduction and of producing antibodies containing human light chains. Further provided are a method for preparing the genetically modified rodent and the use.

A genetically modified plant comprising at least one modification from the natively occurring plant, wherein the at least one modification results in overexpression of at least one chloroplastic translation elongation factor-G (EF-G) protein or active fragment thereof. Methods of producing and using the genetically modified plants are also disclosed herein. The genetically modified plants exhibit increased plant biomass, increased yield, and / or increased photosynthetic capacity over a native, non-genetically modified plant.

1. The name of the design product: label (first rapeseed oil genetically modified rapeseed oil 20L). 2. The use of the design product: bottle label for packaging bottles or cans. 3. The design points of the design product: the combination of shape and pattern. 4. The picture or photo that best indicates the design points: front view. 5. The design product is a flat product, and other views are omitted.

Disclosed herein is a genetically engineered yeast cell capable of producing xylitol, the genetically engineered yeast cell characterized by a genetic modification resulting in overexpression of a natural enzyme having xylitol-5-phosphate phosphatase (X5PP) activity and / or an exogenous polynucleotide sequence encoding an enzyme having xylitol-5-phosphate phosphatase (X5PP) activity. The genetically engineered yeast cell may additionally be engineered to overexpress a native RPE enzyme, to express an exogenous XPDH enzyme, to express an exogenous XKS enzyme, and / or to express an exogenous XDH enzyme.

This invention discloses PagUBC10a The application of genes in regulating the growth and development of poplar trees belongs to the field of agricultural bio-genetic engineering technology. PagUBC10a The application of genes in regulating the growth and development of poplar trees, the PagUBC10a The nucleotide sequence of the gene is shown in SEQ ID NO:1, and is utilized using the... PagUBC10a Genetically modified poplar trees are cultivated using the following methods: cloning poplar trees. PagUBC10a Genes; the aforementioned PagUBC10a The gene is linked to a vector to obtain an overexpression vector; the overexpression vector is transformed into Agrobacterium to obtain Agrobacterium bacterial suspension; the Agrobacterium bacterial suspension is used to inoculate poplar leaves to obtain... PagUBC10a Gene overexpression in poplar. This invention provides a new option for regulating the growth and development of poplar trees and offers a potential target for molecular breeding improvement of poplar traits.

The present invention provides an AutoCell Platform (ACP), an advanced, fully automated, functionally closed system designed to revolutionize the manufacturing of genetically modified cell therapies. This innovative platform integrates automation, closed-loop processing, and novel technologies to address the inefficiencies and high costs of traditional methods. Key features include automated centrifugal seeding for enhanced genetic modification efficiency, microbubble-assisted cell selection for precise cell isolation, and a modular design for scalable amplification across clinical and research environments. By reducing production timelines from 30-40 days to less than 3 days and orders of magnitude in cost, the ACP enables instant manufacturing, decentralization, and broader accessibility. Advanced quality control measures and standardized design ensure compliance and consistent therapeutic outcomes. The ACP supports a variety of applications from CAR-T therapies to regenerative medicine, representing a transformative leap in global accessibility of precision medicine and life-saving cell therapies.